IL2 and neoplasm: It was found that avelumab therapy considerably enhanced cytotoxic activity of NK cells against PD‐L1+ tumor cells of triple‐negative breast cancer (TNBC), and the lytic activity was augmented upon stimulation of NK cells with IL‐2 and IL‐15.